JP2001522857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001522857A5 JP2001522857A5 JP2000520457A JP2000520457A JP2001522857A5 JP 2001522857 A5 JP2001522857 A5 JP 2001522857A5 JP 2000520457 A JP2000520457 A JP 2000520457A JP 2000520457 A JP2000520457 A JP 2000520457A JP 2001522857 A5 JP2001522857 A5 JP 2001522857A5
- Authority
- JP
- Japan
- Prior art keywords
- minutes
- eluent
- mixture
- column
- hplc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9723589.9 | 1997-11-08 | ||
| GBGB9723589.9A GB9723589D0 (en) | 1997-11-08 | 1997-11-08 | Chemical compounds |
| PCT/EP1998/007021 WO1999024449A2 (en) | 1997-11-08 | 1998-11-06 | Adenosine a1 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001522857A JP2001522857A (ja) | 2001-11-20 |
| JP2001522857A5 true JP2001522857A5 (https=) | 2006-01-05 |
Family
ID=10821760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000520457A Pending JP2001522857A (ja) | 1997-11-08 | 1998-11-06 | 化合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6455510B1 (https=) |
| EP (2) | EP1457495A1 (https=) |
| JP (1) | JP2001522857A (https=) |
| KR (1) | KR20010031875A (https=) |
| CN (1) | CN1285843A (https=) |
| AP (1) | AP2000001801A0 (https=) |
| AR (1) | AR011229A1 (https=) |
| AT (1) | ATE273990T1 (https=) |
| AU (1) | AU2048399A (https=) |
| BR (1) | BR9813976A (https=) |
| CA (1) | CA2309200A1 (https=) |
| CO (1) | CO5021135A1 (https=) |
| DE (1) | DE69825780T2 (https=) |
| EA (1) | EA200000392A1 (https=) |
| EE (1) | EE200000285A (https=) |
| ES (1) | ES2222621T3 (https=) |
| GB (1) | GB9723589D0 (https=) |
| HR (1) | HRP20000275A2 (https=) |
| HU (1) | HUP0004082A2 (https=) |
| IL (1) | IL135964A0 (https=) |
| IS (1) | IS5477A (https=) |
| MA (1) | MA26565A1 (https=) |
| NO (1) | NO20002361L (https=) |
| PE (1) | PE20000013A1 (https=) |
| PL (1) | PL340921A1 (https=) |
| SK (1) | SK6722000A3 (https=) |
| TR (1) | TR200002131T2 (https=) |
| WO (1) | WO1999024449A2 (https=) |
| ZA (1) | ZA9810125B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
| GB0106867D0 (en) * | 2001-03-20 | 2001-05-09 | Glaxo Group Ltd | Process |
| US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| NZ556354A (en) | 2001-10-01 | 2008-10-31 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
| EP1375508A1 (en) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | N6-substituted adenosine analogues and their use as pharmaceutical agents |
| US7265111B2 (en) * | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
| FR2842810B1 (fr) * | 2002-07-25 | 2006-01-27 | Inst Nat Sciences Appliq | Nouveaux composes gem difluores, leur procedes de preparation et leurs applications. |
| WO2004016635A2 (en) * | 2002-08-15 | 2004-02-26 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| NZ541651A (en) | 2003-02-03 | 2009-01-31 | Cv Therapeutics Inc | Partial and full agonists of A1 adenosine receptors |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| JP2008512457A (ja) * | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
| US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| CN101938904A (zh) * | 2008-01-09 | 2011-01-05 | PGx健康有限责任公司 | 用a2ar激动剂鞘内治疗神经性疼痛 |
| AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| AU2013243097A1 (en) | 2012-04-03 | 2014-10-09 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| CA3102279A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| US20240247001A1 (en) | 2022-12-16 | 2024-07-25 | Astrazeneca Ab | 2,6,9-trisubstituted purines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3575959A (en) | 1969-05-13 | 1971-04-20 | Merck & Co Inc | 5'-substituted ribofuranosyl nucleosides |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| WO1997033591A1 (en) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| GB9610031D0 (en) * | 1996-05-14 | 1996-07-17 | Glaxo Group Ltd | Chemical compounds |
| GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
-
1997
- 1997-11-08 GB GBGB9723589.9A patent/GB9723589D0/en not_active Ceased
-
1998
- 1998-11-05 PE PE1998001065A patent/PE20000013A1/es not_active Application Discontinuation
- 1998-11-05 MA MA25336A patent/MA26565A1/fr unknown
- 1998-11-05 CO CO98065179A patent/CO5021135A1/es unknown
- 1998-11-05 AR ARP980105590A patent/AR011229A1/es unknown
- 1998-11-05 ZA ZA9810125A patent/ZA9810125B/xx unknown
- 1998-11-06 PL PL98340921A patent/PL340921A1/xx unknown
- 1998-11-06 IL IL13596498A patent/IL135964A0/xx unknown
- 1998-11-06 DE DE1998625780 patent/DE69825780T2/de not_active Expired - Fee Related
- 1998-11-06 AU AU20483/99A patent/AU2048399A/en not_active Abandoned
- 1998-11-06 US US09/530,573 patent/US6455510B1/en not_active Expired - Fee Related
- 1998-11-06 CN CN98812979A patent/CN1285843A/zh active Pending
- 1998-11-06 EE EEP200000285A patent/EE200000285A/xx unknown
- 1998-11-06 EP EP04076482A patent/EP1457495A1/en not_active Withdrawn
- 1998-11-06 TR TR2000/02131T patent/TR200002131T2/xx unknown
- 1998-11-06 EA EA200000392A patent/EA200000392A1/ru unknown
- 1998-11-06 JP JP2000520457A patent/JP2001522857A/ja active Pending
- 1998-11-06 SK SK672-2000A patent/SK6722000A3/sk unknown
- 1998-11-06 EP EP98965151A patent/EP1030857B1/en not_active Expired - Lifetime
- 1998-11-06 HR HR20000275A patent/HRP20000275A2/hr not_active Application Discontinuation
- 1998-11-06 ES ES98965151T patent/ES2222621T3/es not_active Expired - Lifetime
- 1998-11-06 AT AT98965151T patent/ATE273990T1/de not_active IP Right Cessation
- 1998-11-06 BR BR9813976-2A patent/BR9813976A/pt not_active Application Discontinuation
- 1998-11-06 HU HU0004082A patent/HUP0004082A2/hu unknown
- 1998-11-06 AP APAP/P/2000/001801A patent/AP2000001801A0/en unknown
- 1998-11-06 WO PCT/EP1998/007021 patent/WO1999024449A2/en not_active Ceased
- 1998-11-06 CA CA002309200A patent/CA2309200A1/en not_active Abandoned
- 1998-11-06 KR KR1020007004959A patent/KR20010031875A/ko not_active Withdrawn
-
2000
- 2000-05-03 IS IS5477A patent/IS5477A/is unknown
- 2000-05-05 NO NO20002361A patent/NO20002361L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001522857A5 (https=) | ||
| JP2001522858A5 (https=) | ||
| Stein et al. | Phenylacetylglutamine as a constituent of normal human urine | |
| Adam et al. | Routine synthesis of L-[18F] 6-fluorodopa with fluorine-18 acetyl hypofluorite | |
| JP6633497B2 (ja) | プロスタグランジンの精製方法 | |
| Weinstein et al. | N-acyl derivatives of chiral amines as novel, readily prepared phases for the separation of optical isomers by gas chromatography | |
| JPH07252291A (ja) | アントラサイクリノングリコシドの精製法 | |
| RU2001118849A (ru) | Очистка циклопептидных соединений эхинокандина | |
| JP2003534349A (ja) | （ｓｓ，ｒｓ）−ｓ−アデノシル−ｌ−メチオニンの薬剤として許容される塩の調製方法 | |
| Lin et al. | Evaluation of new chiral stationary phases of bonded cyanuric chloride with amino acid and naphthylalkylamine substituents for liquid chromatographic separation of amino acids and amino alcohols as dinitrobenzoyl derivatives | |
| JPH07278081A (ja) | ヨウ素化造影剤の製造方法 | |
| ZA200402006B (en) | Process for the preparation of cilastatin. | |
| CN113061152B (zh) | 一种利用氨基型树脂分离纯化甘油葡萄糖苷的方法 | |
| Swiderski et al. | Polystyrene reverse-phase ion-pair chromatography of chimeric ribozymes | |
| Volland et al. | Stereoselective analysis of fenoprofen and its metabolites | |
| JP3141029B2 (ja) | ペントスタチンの精製方法 | |
| JP2001026567A (ja) | シキミ酸の精製方法 | |
| WO2001030796A1 (en) | A process for preparing acarbose with high purity | |
| Kim et al. | Reversed-phase high performance liquid chromatographic separation of the enantiomers of terbutaline by derivatization with 2, 3, 4, 6-tetra-o-acetyl-β-D-glucopyranosyl isothiocyanate | |
| CN104148037A (zh) | 一种精氨酸键合型亲水色谱固定相及制备方法 | |
| CN119613391B (zh) | 一种恩格列净的纯化方法 | |
| JP2002504855A (ja) | グラディエント溶離法 | |
| JPS62242692A (ja) | モラノリン誘導体の製造法 | |
| JPH10505577A (ja) | Ｄｅａｅ ５ｐｗ陰イオン・イオン交換クロマトグラフィー及び疎水性相互作用クロマトグラフィーを用いるオリゴデオキシヌクレオチドホスホロチオエートの精製 | |
| MIYASHITA et al. | Studies on Iodinated Compounds. I. Improved Procedure for Preparation of Monoiodohistidine |